Fresenius Kabi Expands IV Bag Production Capacity in America Solely to Supply U.S. Market
As part of a nearly $1 billion investment, Fresenius Kabi is expanding its IV bag production by opening a state-of-the-art freeflex® facility in Wilson, NC – backed by two FDA-approved plants in Europe. This new U.S. plant, coming online in 2024, will translate into a significant increase in production capacity, enhanced supply reliability and availability, and shorter lead times for our U.S. customers.
Filled and packaged in America, freeflex® IV bags are beginning to roll off the lines to serve patients and clinicians all across the country.
The most advanced plant of its kind in the U.S., the Wilson facility features the latest production technology with the capacity to produce millions of high quality freeflex® IV bags every year. With vertically integrated in-line automation, these production lines allow Fresenius Kabi to produce IV products in a wide range of sizes and formats, optimizing efficiency and flexibility.
In addition to our Wilson facility, we’ve transformed our New York and Illinois plants with the latest, state-of-the-art technology and built three new distribution centers in Pleasant Prairie, WI, Duncan, SC and Las Vegas, NV.
More Supply, Quicker Response Times
The expansion of freeflex® IV bag production to America is part of a broader strategic initiative to anticipate and meet the needs of the U.S. market. It will help enable us to:
- Respond faster to competitive shortages and spikes in demand.
- Provide additional capacity to flex up the total number of units available to the marketplace.
- Increase product availability to providers which can help avoid delays in therapy for their patients.
- Reduce the length and complexity of our supply chain to shorten lead times.
- Bring our supply of IV bags closer to our end users.
- Provide opportunity to further expand our product lines.
The Products You Need Every Day
In anticipation of the opening of the North Carolina production site, Fresenius Kabi has been rapidly expanding its IV therapy portfolio in the U.S. with a succession of FDA approvals for IV solutions urgently needed by the U.S. market. Our full freeflex® IV bag portfolio will offer more than 100 product codes – many with 36-month shelf life:
- Sodium Chloride Products
- Dextrose Solutions
- Lactated Ringer’s
- Sterile Water
- Mixed Dextrose-Sodium Chloride Products
- Potassium Chloride Products
- Multiple Electrolytes Injection
- Cardioplegic Solution*
- Irrigation Solutions
- And more
*Not for intravenous use
Fresenius Kabi is committed to expanding and improving our production and distribution capabilities right here in America – to ensure patients have the medications and treatments they need, when they need them, as part of
their care.
For the latest information on Fresenius Kabi’s expansion of freeflex® production, please see the Wilson FAQ and Product Code Crosswalk here.
